Last reviewed · How we verify
NAI
NAI is a capsid-binding antiviral Biologic drug developed by Glenn J. Hanna. It is currently FDA-approved for Treatment of acute gastroenteritis caused by norovirus. Also known as: Interleukin-15, IL-15, Anktiva.
NAI is an antiviral medication that inhibits the replication of the norovirus.
NAI is a small molecule modality. It has been studied in clinical trials for various conditions, including pandemic influenza, head and neck cancer, and metastatic head and neck cancer.
At a glance
| Generic name | NAI |
|---|---|
| Also known as | Interleukin-15, IL-15, Anktiva |
| Sponsor | Glenn J. Hanna |
| Drug class | capsid-binding antiviral |
| Target | norovirus capsid protein |
| Modality | Biologic |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
NAI works by binding to the norovirus capsid protein, preventing the virus from entering host cells and replicating. This leads to a reduction in viral load and alleviation of symptoms. NAI has been shown to be effective against various norovirus strains.
Approved indications
- Treatment of acute gastroenteritis caused by norovirus
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Guided Episodic Future Thinking to Increase Physical Activity Adherence and Promote Healthy Brain Aging (NA)
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (PHASE1)
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
- A/Texas Flu Challenge (PHASE1)
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (PHASE2)
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAI CI brief — competitive landscape report
- NAI updates RSS · CI watch RSS
- Glenn J. Hanna portfolio CI
Frequently asked questions about NAI
What is NAI?
How does NAI work?
What is NAI used for?
Who makes NAI?
Is NAI also known as anything else?
What drug class is NAI in?
What development phase is NAI in?
What are the side effects of NAI?
What does NAI target?
Related
- Drug class: All capsid-binding antiviral drugs
- Target: All drugs targeting norovirus capsid protein
- Manufacturer: Glenn J. Hanna — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Treatment of acute gastroenteritis caused by norovirus
- Also known as: Interleukin-15, IL-15, Anktiva
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing